Navigation Links
ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
Date:12/4/2008

mong others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty of predicting the timing or outcome of product development efforts and the FDA or other regulatory agency approval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and/or other governmental regulations applicable to ISTA's facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2007 and its Quarter Reports on Form 10-Q for the quarters ended March 31, June 30, and September 30, 2008.


'/>"/>
SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
2. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
3. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
4. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
5. Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia
6. Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
9. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
10. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
11. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Ore. , July 25, 2014  Semler ... an emerging medical risk assessment company that develops ... patients and evaluating chronic diseases, today reported financial ... ended June 30, 2014. "The ... for Semler," said Doug Murphy-Chutorian , M.D., ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Dr. Michael Gabriel ... Pediatrics, reacts to a recent study, which shows how grief ... - http://photos.prnewswire.com/prnh/20140723/129709 According to ... stress are more likely than others to grow up overweight ... There were two specific types of stress that ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
Breaking Medicine Technology:Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3Dr. Michael Gabriel of GPM Pediatrics, a Noted Staten Island Pediatrics Clinic, Comments on Study, Which Names Grief as a Cause of Obesity in Children 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3
(Date:7/25/2014)... 25, 2014 Florida Hospital and MOSI officially ... organizations for years to come and make a difference in ... $2 million dollar check to provide the support needed to ... enable MOSI to transform the IMAX Dome Theatre from film ... the only IMAX Dome Theatre in the state of Florida, ...
(Date:7/25/2014)... human brain can preserve oxygen to protect itself from ... Although dehydration significantly reduces blood flow to the ... compensates by increasing the amount of oxygen it extracts ... understand a lot more about how the human brain ... author Steven Trangmar, a researcher at Brunel University, said ...
(Date:7/25/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Ibuprofen and Oxcarbazepine Tablets . ... of Ibuprofen and one lot of Oxcarbazepine Tablets, by American ... packaging. Oxcarbazepine is used for the treatment of certain types ... reason for the recall is that Lot #142588, Expiration Date, ...
(Date:7/25/2014)... 25, 2014 A new study conducted by ... that 39 percent of all children in the survey under the ... survey looked at 2,505 children during the years of 2011 and ... of age. The final result was that about two out ... of these children were from lower-income families and were of East ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... results of which are published today in Cancer , ... 55 and 74 who had an abnormal finding on a ... reduced quality of life than did those who were screened ... as a surprise to the researchers. “We expected that participants ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5
... in the Jan. 10 edition of the New England ... treatment and diagnosis of LAM, or lymphangioleiomyomatosis, a progressive ... childbearing years. There currently are no treatments for ... may be going misdiagnosed or undiagnosed. , Researchers ...
... Medicine professor of neurology, Peter Whitehouse, M.D., Ph.D., challenges ... new book, The Myth of Alzheimers: What You Arent ... provocative and ground-breaking new book, Dr. Whitehouse questions current ... brings a new understanding to everything we thought we ...
... The Quantum Group,Inc. (Amex: QGP, QGP.U) ... by Paulson Investment Company, a wholly owned subsidiary ... the lead underwriter for the,December 2007 public offering, ... will separate into its individual component parts; three,shares ...
... Inc. (AIM: TYR), the,pioneer of safer, effective ... achieved development and financial milestones from Arysta,LifeScience ... exclusive global,licensing and co-development agreement to manufacture ... certain horticultural markets., TyraTech is developing ...
... Jan. 10 With an eye to helping,customers ... ( http://www.bragada.com ) is now packing its Luxury ... features than before., All Bragada Luxury mattresses ... built into the fabric. One of the softest ...
... 9 The perception that,U.S. doctors are unwilling to ... untrue, according to a new study funded by HHS, ... doctors think that current systems to report and share,information ... with their colleagues. Consequently, important information,about medical errors and ...
Cached Medicine News:Health News:New research demonstrates potential diagnosis, treatment benefits 2Health News:New research demonstrates potential diagnosis, treatment benefits 3Health News:New research demonstrates potential diagnosis, treatment benefits 4Health News:International brain aging expert challenges the existence of Alzheimer's as a 'disease' 2Health News:International brain aging expert challenges the existence of Alzheimer's as a 'disease' 3Health News:The Quantum Group, Inc. Announces Separation of Units 2Health News:The Quantum Group, Inc. Announces Separation of Units 3Health News:TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience 2Health News:TyraTech Achieves Insecticide Development and Financial Milestones With Partner Arysta LifeScience 3Health News:Bragada(R) Luxury Mattress, Inc. Upgrades Luxury and Ultra Luxury Collections 2Health News:Physicians Want to Learn From Medical Mistakes But Say Current Error-Reporting Systems are Inadequate 2Health News:Physicians Want to Learn From Medical Mistakes But Say Current Error-Reporting Systems are Inadequate 3
This is the modular VICTOR2 multilabel counter with the TR-fluorometry, stacker and robot loading options.The addition of a xenon flash lamp brings the time-resolved fluorescence counting mode to th...
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
... readers available today operate with either one, ... speed) or use an imaging process to ... sensitivity and the individual signals can overlap). ... miniature lens array containing 96 parallel micro-objectives. ...
The Columbus microplate strip washer is for individual strips or whole plates.Programming and control are via an alphanumeric display. Up to 30 methods are stored for easy recall....
Medicine Products: